Evidence map›Paper›PMID 40469570›Full record

ArticleBiochemia medica2025

Telomere length and oxidative stress in small cell lung cancer patients: changes through chemotherapy cycles compared to healthy controls.

Azra Guzonjić, Dragana Jovanović, Ivana Simić, Vesna Ćeriman Krstić, Natalija Samardzić, Barbara Ostanek, Janja Marc, Miron Sopić, Jelena Kotur Stevuljević

Abstract read
In one paragraph

Article in Biochemia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Azra GuzonjićDepartment for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Dragana JovanovićInternal Medicine Clinic "Akta Medica", Belgrade, Serbia.
Ivana SimićMerck Sharp & Dohme d.o.o., Medical Affairs, Belgrade, Serbia.
Vesna Ćeriman KrstićFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Natalija SamardzićClinic for Pulmonology, University Clinical Center of Serbia, Belgrade, Serbia.
Barbara OstanekDepartment of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Janja MarcDepartment of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Miron SopićDepartment for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Jelena Kotur StevuljevićDepartment for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Small cell lung cancer (SCLC) is an aggressive malignant disease with poor survival outcomes. The aim of this study was to investigate leukocyte telomere length (LTL) and redox status parameters during chemotherapy and evaluate their prognostic potential based on the hypothesis that shorter LTL and oxidative stress burden correlate with poorer survival. Materials and methods: This longitudinal study included 60 SCLC patients and 73 healthy controls. Leukocyte telomere length was measured by quantitative PCR (qPCR) method, while redox status parameters (MDA - malondialdehyde, IMA - ischemia-modified albumin, PON1 - paraoxonase 1, redox index) were determined by spectrophotometric methods before, after two and after four cycles of chemotherapy. Results: All measured parameters showed significant differences between patients and controls, except the oxy-score (P < 0.001). Significant differences in IMA, PON1 and redox index were observed between SCLC patient groups at different time points (P < 0.001). Significant differences in IMA and PON1 were observed between SCLC survival groups, with higher values found in survivors after two chemotherapy cycles (P < 0.001). Redox index was the highest in the pre-chemo group (P = 0.019). Among patients who died, PON1 activity differed significantly between those who died within 2 months and after 4 months (P = 0.028). Kaplan-Meier analysis showed that LTL and PON1 were significant predictors of survival, with values below the 25th percentile associated with a higher risk of death. Conclusions: Leukocyte telomere length and PON1 are potential prognostic biomarkers for SCLC survival, suggesting their potential use in non-invasive biomarker panels for improved patient stratification.

Indexed as

Lung NeoplasmsOxidative StressSmall Cell Lung CarcinomaTelomereTelomere HomeostasisAdultAgedAryldialkylphosphataseCase-Control StudiesFemaleHumansLeukocytesLongitudinal StudiesMaleMiddle AgedOxidation-ReductionAryldialkylphosphatasePON1 protein, humancisplatin/etoposide regimenredox statussmall cell lung cancertelomere length

Identifiers

PMID40469570
PMCPMC12131383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.